Influenza market
Jul 11, 2019
Osivax raises USD 9M; Smyraf launched; Revolution secures USD 100M
Osivax raises USD 9 M to boost its universal flu vaccine approach France based biotech startup company Osivax, has secured USD 9 million in Series A financing. A Belgian-based firm Noshaq along with Anaxago, an innovative investment platform led the financing. The proceeds will be used to further advance the cl...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
